Supreme Court Bans Patanjali Advertisements | Patanjali Share Prices Fall

Under Segment 4 of the DOMA, there is a forbiddance against publishing misleading advertisements connecting with a medication. This is portrayed as an advertisement that “straightforwardly or by implication sends a mixed signal in regards to the genuine person of the medication,” “makes a bogus case for the medication,” or “is otherwise misleading or misleading in any material specific.”

Who Upvoted this Story